Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study

European Psychiatry

Volumn 27, Issue 4, 2012, Pages 267-274

  Albaiges, L ^a   Alday, M O ^a   Alonso, M ^a   Alvarez P ^a   Alvarez S ^a   Alzate G , ^a   Anguiano J B , ^a   Anton C ^a   Aragues E , ^a   Asensio F , ^a   Bardolet C , ^a   Barragan J ^a   Bellido J A , ^a   Bordas R , ^a   Busto J , ^a   Cadevall J , ^a   Canete J ^a   Capllonch I , ^a   Carmona C , ^a   Carrasco E , ^a   Carrillo A , ^a   Castillo C , ^a   Chinea E R , ^a   Cleris M , ^a   De Dios C , ^a   De Una M A ^a   Diaz N ^a   Domenech J R ^a   Ducaju M , ^a   Echeveste M , ^a   Fernandez A ^a   Fernandez Cuevas A ^a   Fernandez Villamor R ^a   Figuerido J L , ^a   Fluvia J , ^a   Franch J I , ^a   Galan F ^a   Garcia I ^a   Garcia J ^a   Garcia Portilla M P ^a   Gil P , ^a   Gomez Trigo J ^a   Gonzalez F A ^a   Gonzalez G ^a   Gonzalez P ^a   Gonzalez T ^a   Gonzalez Quiros M ^a   Graizer O , ^a   Hernandez C ^a   Hernandez J L ^a   Iglesias C , ^a   Irurita J , ^a   Justo M I , ^a   Karim M , ^a   Larrazabal L M , ^a   Lizarraga J , ^a   Lojo F M , ^a   Lopez I ^a   Lopez J ^a   Lopez L ^a   Loro M , ^a   Martin E ^a   Martin F ^a   Martinez A ^a   Martinez de Morentin J J ^a   Martinez J L ^a   Martinez J M ^a   Martinez M ^a   Martinez R ^a   Medina G , ^a   Medina J L , ^a   Megia P ^a   Mendezona J I , ^a   Merino M J , ^a   Messays M , ^a   Misiego J M , ^a   Mongil J M , ^a   Montejo A L , ^a   Montes J M , ^a   More M A , ^a   Moyano L , ^a   Natividad M C , ^a   Pacheco L , ^a   Palao D J , ^a   Palomo A L , ^a   Parramon G ^a   Pascual G , ^a   Pastor A , ^a   Pastor F J , ^a   Peralta E , ^a   Perez E ^a   Prieto N , ^a   Rodriguez E ^a   Rodriguez J C ^a   Roig A , ^a   Rojano P , ^a   Rubio T , ^a   Ruiz F C , ^a   Ruiz J M , ^a   Salesansky A , ^a   Salgado M C , ^a   San Narciso G I , ^a   Sanchez J M ^a   Sanz J , ^a   Shabiaga P , ^a   Silveira J R , ^a   Sopelana P A , ^a   Soto J A , ^a   Sotomayor E , ^a   Teba F , ^a   Valdelomar M , ^a   Valle J R , ^a   Vicente F J , ^a   Villagran D , ^a   Villamor A , ^a   Bobes, J ^b   Arango, C ^c   Aranda, P ^d   Carmena, R ^e   Garcia Garcia, M ^f   Rejas, J ^g   more..

^a Centro de Investigacion Biomedica en Red de Salud Mental CIBERSAM ^*

^b UNIVERSITY OF OVIEDO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f Operations Department   (Spain)

^g PFIZER INC   (United States)

Author keywords

Antipsychotic treatment; Cardiovascular risk; Mental status; Metabolic syndrome; Outpatients; Schizoaffective disorders

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; POPULATION RISK; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCORING SYSTEM; SYSTEMATIC CORONARY RISK EVALUATION SCORE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84860326668     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.09.001     Document Type: Article

References (57)

1. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062. IDF Epidemiology task Force Consensus Group.
2. Alegría E., Cordero A., Laclaustra M., Grima A., León M., Casasnovas J.A., et al. En representación de los investigadores del registro MESYAS. Prevalencia del síndrome metabólico en población laboral española: registro MESYAS. Rev Esp Cardiol 2005, 58:797-806.
3. álvarez E.E., Ribas L., Serra L. Prevalence of the metabolic syndrome in the population of Canary Islands, Spain. Med Clin (Barc) 2003, 120:172-174.
4. álvarez-Cosmea A., López V., Suárez S., Arias T., Prieto M.A., Díaz L. Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP-III y la OMS. Med Clin (Barc) 2005, 124:368-370.
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
6. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, Author, Washington, DC. 4th text rev. ed.
7. Aranceta J., Perez C., Serra L., Ribas L., Quiles J., Vioque J., et al. Prevalence of obesity in Spain: results of the SEEDO 2000 study. Med Clin (Barc) 2003, 120:608-612.
8. Aranceta J., Pérez-Rodrigo C., Foz-Saal M., Mantilla T., Serra L.l., Moreno B., et al. Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA. Med Clin (Barc) 2004, 123:686-691.
9. Ascaso J.F., Gabriel R., Franch J., Godoy A., Fernández de Bobadilla J., Ortega R., et al. Grado de concordancia de los distintos criterios que definen el síndrome metabólico en el estudio DESIRE [abstract]. Av Diabetologia 2004, 20:23.
10. Bai Y.M., Chen T.T., Yang W.S., Chi Y.C., Lin C.C., Liou Y.J., et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009, 111:1-8.
11. Basu R., Brar J.S., Chengappa R., John V., Parepally H., Gershon S., et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord 2004, 6:314-318.
12. Bobes J., Rejas J., Garcia-Garcia M., Rico-Villademoros F., García-Portilla M.P., Fernández I., et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003, 62:77-88.
13. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90:162-173.
14. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
15. Cabrera de León A., Rodriguez-Perez M.C., del Castillo-Rodriguez J.C., Brito-Diaz B., Perez-Mendez L.I., Muros de Fuentes M., et al. Coronary risk in the population of the Canary Islands, Spain, using the Framingham function. Med Clin 2006, 126:535-536.
16. Coca M.M., Hernanz P., Vega M., Suárez C. Prevalencia de síndrome metabólico en la población de un centro de atención primaria urbano. Aten Primaria 2005, 35:436-437.
17. Cohn T., Remington G., Zipursky R.B., Azad A., Connolly P., Wolever T. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006, 51:382-386.
18. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
19. De Hert M., Schreurs V., Vancampfort D., Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8:15-22.
20. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Möller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
21. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado K., Lucksted A., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000, 26:903-912.
22. Enger C., Weatherby L., Reynolds R.F., Glasser D.B., Walker A.M. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004, 192:19-27.
23. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005, 7:424-430.
24. Garcia-Portilla M.P., Saiz P.A., Benabarre A., Sierra P., Perez J., Rodriguez A., et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord 2008, 106:197-201.
25. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80:45-53.
26. Guy W. Early Clinical Drug Evaluation (ECDEU). Assessment Manual. Rockville. Nat Inst Ment Health 1976, 218-222.
27. Hanssens L., van Winkel R., Wampers M., Van Eyck D., Scheen A., Reginster J.Y., et al. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder. Schizophr Res 2008, 106:308-314.
28. Holt R.I. Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Br J Psychiatry 2005, (Suppl. 47):S55-S63.
29. International Conference on Harmonization (ICH): E9 Statistical Principles for Clinical Trials. Rockville (USA). Food Drug Adm;1998.
30. Kane J.M., Barrett E.J., Casey D.E., Correll C.U., Gelenberg A.J., Klein S., et al. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004, 65:1447-1455.
31. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
32. Kilbourne A.M., Brar J.S., Drayer R.A., Xu X., Post E.P. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics 2007, 48:412-417.
33. Lamberti J.S., Crilly J.F., Maharaj K., Olson D., Wiener K., Dvorin S., et al. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 2004, 65:702-706.
34. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., et al. Prevalence of the Metabolic Syndrome among patients receiving clozapine. Am J Psychiatry 2006, 163:1273-1276.
35. Levkovitz Y., Ben-Shushan G., Hershkovitz A., Isaac R., Gil-Ad I., Shvartsman D., et al. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci 2007, 36:305-312.
36. Lorenzo C., Serrano-Ríos M., Martínez-Larrad M.T., Gabriel R., Williams K., Gómez-Gerique J.A., et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003, 11:1480-1487.
37. Mackin P., Bishop D., Watkinson H., Gallagher P., Ferrier I.N. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007, 191:23-29.
38. Martínez-Larrad M.T., Fernández-Pérez C., González-Sánchez J.L., López A., Fernández-álvarez J., Riviriego J., et al. Prevalence of the metabolic syndrome (ATP-III criteria). Population-based study of rural and urban areas in the Spanish province of Segovia. Med Clin (Barc) 2005, 125:481-486.
39. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
40. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009, 119:4-14.
41. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005, 80:9-18.
42. National Institutes of Health Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143-3421.
43. Peralta V., Cuesta M. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenia patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994, 22:171-177.
44. Pérez-Fernández R., Mariño A.F., Cadarso-Suárez C., Botana M.A., Tome M.A., Solache I., et al. Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases. J Hum Hypertens 2007, 21:366-373.
45. Ribeiro P.J., Lopes F. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007, 29:330-336.
46. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
47. Saari K.M., Lindeman S.M., Viilo K.M., Isohanni M.K., Järvelin M.R., Laurén L.H., et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005, 66:559-563.
48. SEA. Obesidad y riesgo cardiovascular. Documento consenso. Sociedad Española de Arterioesclerosis; 2003.
49. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002, 159:561-566.
50. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-622.
51. Sutherland J.P., McKinley B., Eckel R.H. The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2004, 2:82-104.
52. Suvisaari J.M., Saarni S.I., Perala J., Suvisaari J.V., Harkanen T., Lonnqvist J., et al. Metabolic Syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007, 68:1045-1055.
53. van Winkel R., van Os J., Celic I., Van Eyck D., Wampers M., Scheen A., et al. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008, 69:1319-1327.
54. Vara-González L., Muñoz Cacho P., Sanz de Castro S. Arterial hipertensión prevalence, detection, treatment and control in Cantabria, Spain, 2002. Rev Esp Salud Publica 2007, 81:211-219.
55. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
56. Wirshing D.A. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004, 65:13-26.
57. WMA. Policy. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects; 2004. http://www.wma.net/e/policy/b3.htm.